Lonnie Moulder (L) and Hua Mu

Lon­nie Moul­der woos a sea­soned de­vel­op­ment ex­pert from Hill­house­'s US/Chi­na play to helm his start­up

Back in 2010, when Tesaro was still a nascent biotech start­up, Lon­nie Moul­der re­mem­bers tak­ing due dili­gence trips to Chi­na to meet and un­der­stand com­pa­nies that could be po­ten­tial com­mer­cial­iza­tion part­ners for their im­muno-on­col­o­gy pro­grams. One of them was Hutchi­son Chi­na MediTech, or Chi-Med, which was then led by CEO Saman­tha Du and CMO Hua Mu.

A lot has changed since then.

Tesaro end­ed up strik­ing a pact with Zai Lab — Du’s pi­o­neer­ing US/Chi­na biotech — be­fore get­ting snapped up by Glax­o­SmithK­line for $5 bil­lion. Chi-Med has just re­named it­self to HutchMed. Moul­der him­self set up his lat­est biotech start­up, dubbed Zenas, to have a go at a ver­sion 2.0 of the glob­al ap­proach he had ex­per­i­ment­ed with at Tesaro.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.